Madrigal Pharms

MDGL NASDAQ
103.11
-3.50
-3.28%
After Hours: 103.11 0 0.00% 16:50 05/17 EDT
Open
105.32
Prev Close
106.61
High
107.45
Low
101.75
Volume
149.03K
Avg Vol (3M)
214.53K
52 Week High
325.98
52 Week Low
91.56
% Turnover
0.97%
Market Cap
1.59B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Madrigal Pharms MDGL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
MORE >

Recently

Name
Price
%Change